LBL-019

· Nanjing Leads Biolabs Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LBL-019, covering 2026-02-02 to 2026-02-02. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors [Phase 1, Phase 2]

See pricing